Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal

Molecular Pharmacology

Volumn 77, Issue 5, 2010, Pages 864-873

  Navarro Zaragoza, Javier ^a   Núñez, Cristina ^a   Laorden, M Luisa ^a   Milanés, M Victoria ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; MORPHINE; NALOXONE; NORADRENALIN; PLACEBO; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN RELEASE; DRUG WITHDRAWAL; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOHISTOCHEMISTRY; IRRITABILITY; MAGNOCELLULAR NUCLEUS; MALE; MORPHINE ADDICTION; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; SOLITARY TRACT NUCLEUS; STRESS; WEIGHT CHANGE; WESTERN BLOTTING;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRAIN; BRAIN STEM; CORTICOSTERONE; IODINE RADIOISOTOPES; MALE; METHOXYHYDROXYPHENYLGLYCOL; MORPHINE; NOREPINEPHRINE; PROTO-ONCOGENE PROTEINS C-FOS; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TYROSINE 3-MONOOXYGENASE;

EID: 77951055922     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.062463     Document Type: Article

References (37)

1. Aston-Jones G and Harris GC (2004) Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 47:167-179. (Pubitemid 39298262)
2. Bale TL and Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:525-557.
3. Cleck JN and Blendy JA (2008) Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest 118:454-461.
4. Contarino A and Papaleo F (2005) The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opioid withdrawal. Proc Natl Acad Sci USA 102:18649-18654. (Pubitemid 43011280)
5. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, et al. (1999) The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140:79-86. (Pubitemid 29011144)
6. Frenois F, Cador M, Caille S, Stinus L, and Le Moine C (2002) Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal. Eur J Neurosci 16:1377-1389. (Pubitemid 35340859)
7. Funada M, Hara C, and Wada K (2001) Involvement of corticotropin- releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur J Pharmacol 430:277-281. (Pubitemid 33050050)
8. Gallagher JP, Orozco-Cabal LF, Liu J, and Shinnick-Gallagher P (2008) Synaptic physiology of central CRH system. Eur J Pharmacol 583:215-225.
9. Gold LH, Stinus L, Inturrisi CE, and Koob GF (1994) Prolonged tolerance, dependence, and abstinence following subcutaneous morphine pellet implantation in the rat. Eur J Pharmacol 253:45-51. (Pubitemid 24063426)
10. Grakalic I, Schindler C, Baumann M, Rice K, and Riley A (2006) Effects of stress modulation on morphine-induced conditioned place preferences and plasma corticosterone levels in Fischer, Lewis, and Sprague-Dawley rat strains. Psychopharmacology 189:277-286. (Pubitemid 44772811)
11. Gray TS and Magnuson DJ (1987) Neuropeptide neuronal efferents from the bed nucleus of the stria terminalis and central amygdaloid nucleus to the dorsal vagal complex in the rat. J Comp Neurol 262:365-374. (Pubitemid 17141426)
12. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YPL, and Duman RS (2000) Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74:199-208. (Pubitemid 30012770)
13. Koob GF (1999) Stress, corticotropin-releasing factor, and drug addiction. Ann NY Acad Sci 897:27-45.
14. Koob GF (2008) A role for brain stress system in addiction. Neuron 59:11-34.
15. Laorden ML, Castells MT, Martínez MD, Martínez PJ, and Milanés MV (2000a) Activation of c-Fos expression in hypothalamic nuclei by μ- and κ-receptor agonists. Correlation with catecholaminergic activity in the hypothalamic paraventricular nucleus. Endocrinology 141:1366-1376.
16. Laorden ML, Castells MT, and Milanés MV (2002a) Effects of morphine and morphine withdrawal on brainstem neurons innervating hypothalamic nuclei that control the pituitary-adrenocortical axis in rats. Br J Pharmacol 136:67-75.
17. 2-adrenoceptors. J Pharmacol Exp Ther 293:578-584.
18. Laorden ML, Núñez C, Almela P, and Milanés MV (2002b) Morphine withdrawal-induced c-Fos expression in the hypothalamic paraventricular nucleus is dependent on the activation of catecholaminergic neurones. J Neurochem 83:132-140.
19. Lavicky J and Dunn AJ (1993) Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis. J Neurochem 60:602-612. (Pubitemid 23030957)
20. Lu L, Liu D, Ceng X, and Ma L (2000) Differential role of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 12:4398-4404. (Pubitemid 32037848)
21. Maldonado R (1997) Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 1:91-104.
22. Núñez C, Foldes A, Laorden ML, Milanes MV, and Kovács KJ (2007a) Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J Neurochem 101:1060-1071. (Pubitemid 46683869)
23. Núñez C, Földes A, Pérez-Flores D, García-Borrón JC, Laorden ML, Kovács KJ, and Milanés MV (2009) Elevated glucocorticoid levels are responsible for induction of tyrosine hydroxylase (TH) mRNA expression, phosphorylation, and enzyme activity in the nucleus of the solitary tract (NTS-A2) during morphine withdrawal. Endocrinology 150:3118-3127.
24. Núñez C, Laorden ML, and Milanes MV (2007b) Regulation of Serine (Ser)-31 and Ser40 tyrosine hydroxylase phosphorylation during morphine withdrawal in the hypothalamic paraventricular nucleus and nucleus tractus solitarius-A2 cell group. Role of ERK1/2. Endocrinology 148:5780-5793. (Pubitemid 350146166)
25. Owens MJ and Nemeroff CB (1991) Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 43:425-473.
26. Palkovits M (1973) Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 59:449-450.
27. Paxinos G and Watson C (2007) The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego.
28. Rusnak M, Kvetnansk R, Jelokova J, and Palkovits M (2001) Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats. Brain Res 899:20-35. (Pubitemid 32324144)
29. Sauvage M and Steckler T (2001) Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic, and noradrenergic neurons of the murine basal forebrain and brainstem nuclei: potential implication for arousal and attention. Neuroscience 104:643-652. (Pubitemid 32607418)
30. Skelton KH, Oren D, Gutman DA, Easterling K, Holtzman SG, Nemeroff CB, and Owens MJ (2007) The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. Eur J Pharmacol 571:17-24. (Pubitemid 47284048)
31. Smith RJ and Aston-Jones G (2008) Noradrenergic transmission in the extended amygdala: role in increased drug seeking and relapse during protracted drug abstinence. Brain Struct Funct 213:43-61.
32. Stinus L, Cador M, Zorrilla EP, and Koob GF (2005) Buprenorphine and CRF1 antagonists block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30:90-98. (Pubitemid 40024403)
33. Tilders FJ, Berkenbosch F, Vermes I, Linton EA, and Smelek PG (1985) Role of epinephrine and vasopressin in the control of the pituitary-adrenal response to stress. Fed Proc 44:155-168. (Pubitemid 15170668)
34. Vale W, Spiess J, Rivier C, and Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213:139719. (Pubitemid 12243637)
35. Van Pett K, Viau V, Bittencourt JC, Li HY, Arias C, Prins GS, Perrin M, Vale W, and Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191-212.
36. Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, and Holsboer F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171-181.
37. Zorrilla EP and Koob GF (2004) The therapeutic potential of CRF1 antagonists for anxiety. Expert Opin Investig Drugs 13:799-828. (Pubitemid 39028932)